A Phase I Trial to Evaluate the Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Neonates at Risk of Acquiring HIV-1 Infection
Phase of Trial: Phase I
Latest Information Update: 07 Nov 2019
Price : $35 *
At a glance
- Drugs Raltegravir (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics; Registrational
- 07 Nov 2019 Results (n=6) assessing pharmacokinetic parameters were published in the JAIDS
- 08 Jan 2019 Planned End Date changed from 12 Aug 2019 to 30 Apr 2020.
- 08 Jan 2019 Planned primary completion date changed from 1 Jun 2018 to 31 Mar 2020.